KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read More
Myriam joined Selexis in 2012 as project leader, managing and coordinating research, experimental design, process completion, data treatment and reporting for partner projects. Subsequently, she held roles of increasing responsibility, serving as scientist in vector engineering and later as operations program manager and operations director, coordinating partner-oriented mammalian cell line generation and whole-genome sequencing programs. In the latter roles, Myriam also supported intellectual property activities. Previously, she was scientist at École Polytechnique fédérale de Lausanne (EPFL) and project leader, gene expression and analytics at ExcellGene SA. She held postdoctoral positions at Centre of Immunology Marseille-Luminy, University of Geneva-CMU and Geneva Hospital. Myriam earned her PhD in botanical sciences from the University of Liège, Belgium.
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2023 Selexis SA. All Rights Reserved.